



GlaxoSmithKline Pharmaceuticals Ltd.

GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

15th June 2021

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Subject: Submission of Disclosure on Related Party Transactions

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the attached Related Party Transactions, on consolidated basis, drawn in accordance with applicable accounting standards for period ended 31st March 2021.

Kindly take submission on record.

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni

Vice President – Administration, Real Estate
& Company Secretary

Pursuant to Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Related party disclosures, as required by IND AS 24, "Related Party Disclosures", notified under Section 133 of the Companies Act, 2013 are given below:

1 Relationships (during the year):

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company :

Glaxo Group Limited, U.K.
GlaxoSmithKline Pte Limited, Singapore
Eskaylab Limited, U.K.
Burroughs Wellcome International Limited, U.K.

Holding company / ultimate holding company of the above shareholders

GlaxoSmithKline Plc, U.K.*
GlaxoSmithKline Finance Plc, U.K.*
Setfirst Ltd, U.K.*
SmithKline Beecham Limited, U.K.
Wellcome Limited, U.K.*
The Wellcome Foundation Limited, U.K.*
Wellcome Consumer Healthcare Limited, U.K.*

* no transactions during the year

(ii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year:

GlaxoSmithKline Asia Private Limited, India
GlaxoSmithKline Brasil Ltda, Brazil*
GlaxoSmithKline Consumer Healthcare Limited, India*
GlaxoSmithKline Biologicals S.A., Belgium
GlaxoSmithKline Pharmaceuticals S.A., Belgium
GlaxoSmithKline Services Unlimited, U.K.
Glaxo Operations UK Limited, U.K.
Laboratoire GlaxoSmithKline S.A.S., France*
GlaxoSmithKline Pharmaceutical Sdn Bhd, Malaysia
GlaxoSmithKline Export Limited, U.K.
SmithKline Beecham Pharmaceuticals, U.S.A
GlaxoSmithKline Latin America S.A*
GlaxoSmithKline Pakistan Limited, Pakistan*
GlaxoSmithKline Research & Development Ltd, U.K.
GlaxoSmithKline Corporate Centre, U.S.A*
GlaxoSmithKline Philippines Inc., Philippines*
GlaxoSmithKline Australia Pty Limited, Australia*
GlaxoSmithKline Canada Inc, Canada*
GlaxoSmithKline Trading Services Limited, Ireland
GlaxoSmithKline Limited, Hong Kong*
GlaxoSmithKline South Africa (Pty) Ltd, South Africa
GlaxoSmithKline LLC, U.S.A*
GlaxoSmithKline Limited, Kenya*
GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria*
Stiefel India Private Limited, India
GSK India Global Services Private Limited
Glaxo Wellcome Ceylon Ltd., Sri Lanka*
US Pharmaceuticals, U.S.A.*
GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka
ViiV Healthcare Limited, UK *
US GMS Financial Services, U.S.A.*
GlaxoSmithKline S.A.E., Egypt*
GlaxoSmithKline Inc, Philadelphia*
GlaxoSmithKline Manufacturing SPA, Italy*
GlaxoSmithKline Intellectual Property Limited*
GlaxoSmithKline (Thailand) Ltd

* no transactions during the year

Related Party disclosures (continued)

(iii) Directors and members of GSK India Leadership Team :

Directors:

Ms. P. Thakur #
 Mr S Venkatesh # (w.e.f. April 1, 2020)
 Mr. M. Dawson (w.e.f. January 28, 2021)
 Ms. S. Maheshwari ((w.e.f. May 18, 2020)
 Mr. N. Kaviratne
 Mr. P. Bhide
 Ms. R. S. Karnad
 Mr. A. N. Roy
 Mr. D. Sundaram
 Mr. S. Williams
 Mr. R. Krishnaswamy # (upto January 27, 2021)
 Ms. A. Bansal (upto March 29, 2020)
 Mr. A. Vaidheesh # (upto March 31, 2020)

Also member of GSK India Leadership Team

GSK India Leadership Team:

Mr. A. Nadkarni
 Mr. R. D'souza
 Mr. S. Dheri
 Ms. S. Choudhary
 Mr. B. Kotak (upto March 31, 2021)
 Mr. A. Iyer (upto March 31, 2021)
 Mr. S. Balasubramanian
 Mr. A. Kashyap (w.e.f. May 28, 2020)
 Mr. B. Akshikar (w.e.f. December 1, 2020)
 Mr. C. Sharma (w.e.f. December 1, 2020)
 Mr. N. Hindia (w.e.f. June 01, 2018 upto March 22, 2020 and w.e.f. January 4, 2021)
 Ms. M. Priyam (upto August 31, 2020)
 Ms. D. Jakate (upto January 31, 2021)
 Ms. S. Zota (w.e.f. March 23, 2020 upto December 31, 2020)
 Mr. G. Kotian (w.e.f. October 01, 2018 upto October 31, 2019)
 Mr. N. Sudrik (w.e.f. October 01, 2018 upto October 31, 2019)
 Ms. S. Ghosh (w.e.f. August 25, 2020 upto December 1, 2020)

2 The following transactions were carried out with the related parties in the ordinary course of business:

(i) Dividend paid to parties referred to in item 1(i) above:

(Rupees in lakhs)

	Year ended March 31, 2021	Year ended March 31, 2020
Glaxo Group Limited, U.K.	219,49.38	121,94.10
GlaxoSmithKline Pte Limited, Singapore	171,37.45	95,20.80
Eskaylab Limited, U.K.	42,33.60	23,52.00
Burroughs Wellcome International Limited, U.K.	24,19.20	13,44.00

(ii) Details relating to parties referred to in items 1(i) and 1(ii) above:

(Rupees in lakhs)

	Holding company/ultimate holding company 1(i)		Other companies in the GSK Group 1(ii)	
	Year ended March 31, 2021	Year ended March 31, 2020	Year ended March 31, 2021	Year ended March 31, 2020
1 Purchase of materials/traded goods	-	-	629,73.24	634,52.35
2 Sale of materials/sale of products	-	-	995.96	23.92
3 Sale of laptops	-	-	-	28.56
4 Expenses recharged to other companies	-	36.05	17,62.76	27,93.64
5 Expenses recharged by other companies	49.56	-	96,35.07	74,67.46
6 Manufacturing charges recovered	-	-	4,31.95	13,84.54
7 Clinical research and data management recoveries	-	-	9,36.45	8,98.26
8 Liabilities written back	-	-	77.24	-
9 Employee benefit liabilities transferred to a related party	-	-	19.86	13.51
10 Outstanding receivables at the period end	-	-	17,74.40	7,30.82
11 Outstanding payables at the period end	46.17	-	118,94.44	56,77.24
12 Cross charges recoverable at the period end	-	-	4.82	1,25.22

(iv) Details relating to persons referred to in item 1(iii) above:

(Rupees in lakhs)

	Year ended March 31, 2021	Year ended March 31, 2020
1 Remuneration/commission/sitting fees	37,93.20	40,91.89
2 Payments under the long-term incentive plan	2,95.47	5,16.49

Pursuant to Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Related party disclosures, as required by IND AS 24, "Related Party Disclosures", notified under Section 133 of the Companies Act, 2013 are given below:

1 Relationships (during the year):

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company :

Glaxo Group Limited, U.K.
GlaxoSmithKline Pte Limited, Singapore
Eskaylab Limited, U.K.
Burroughs Wellcome International Limited, U.K.

Holding company / ultimate holding company of the above shareholders

GlaxoSmithKline Plc, U.K. *
GlaxoSmithKline Finance Plc, U.K.*
Setfirst Ltd, U.K. *
SmithKline Beecham Limited, U.K.
Wellcome Limited, U.K.*
The Wellcome Foundation Limited, U.K.*
Wellcome Consumer Healthcare Limited, U.K.*

* no transactions during the year

(ii) Subsidiary of the Company :

Biddle Sawyer Limited, a wholly owned subsidiary of the Company

(iii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year:

GlaxoSmithKline Asia Private Limited, India
GlaxoSmithKline Brasil Ltda, Brazil*
GlaxoSmithKline Consumer Healthcare Limited, India*
GlaxoSmithKline Biologicals S.A., Belgium
GlaxoSmithKline Pharmaceuticals S.A., Belgium
GlaxoSmithKline Services Unlimited, U.K.
Glaxo Operations UK Limited, U.K
Laboratoire GlaxoSmithKline S.A.S., France*
GlaxoSmithKline Pharmaceutical Sdn Bhd, Malaysia
GlaxoSmithKline Export Limited, U.K.
SmithKline Beecham Pharmaceuticals, U.S.A
GlaxoSmithKline Latin America S.A*
GlaxoSmithKline Pakistan Limited, Pakistan*
GlaxoSmithKline Research & Development Ltd, U.K
GlaxoSmithKline Corporate Centre, U.S.A*
GlaxoSmithKline Philippines Inc., Philippines*
GlaxoSmithKline Australia Pty Limited, Australia*
GlaxoSmithKline Canada Inc, Canada*
GlaxoSmithKline Trading Services Limited, Ireland
GlaxoSmithKline Limited, Hong Kong*
GlaxoSmithKline South Africa (Pty) Ltd, South Africa
GlaxoSmithKline LLC, U.S.A*
GlaxoSmithKline Limited, Kenya*
GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria*
Stiefel India Private Limited, India
GSK India Global Services Private Limited
Glaxo Wellcome Ceylon Ltd., Sri Lanka*
US Pharmaceuticals, U.S.A.*
GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka
ViiV Healthcare Limited, UK *
US GMS Financial Services, U.S.A.*
GlaxoSmithKline S.A.E., Egypt*
GlaxoSmithKline Inc, Philadelphia*
GlaxoSmithKline Manufacturing SPA, Italy*
GlaxoSmithKline Intellectual Property Limited*
GlaxoSmithKline (Thailand) Ltd

* no transactions during the year

(iv) Directors and members of GSK India Leadership Team :

Directors:

Ms. P. Thakur #
Mr S Venkatesh # (w.e.f. April 1, 2020)
Mr. M. Dawson (w.e.f. January 28, 2021)
Ms. S.Maheshwari ((w.e.f. May 18, 2020)
Mr. N. Kaviratne
Mr. P. Bhide
Ms. R. S. Karnad
Mr. A. N. Roy
Mr. D. Sundaram
Mr. S. Williams
Mr. R. Krishnaswamy # (upto January 27, 2021)
Ms. A. Bansal (upto March 29, 2020)
Mr. A. Vaidheesh # (upto March 31, 2020)

Also member of GSK India Leadership Team

GSK India Leadership Team:

Mr. A. Nadkarni
Mr. R. D'souza
Mr. S. Dheri
Ms. S. Choudhary
Mr. B. Kotak
Mr. A. Iyer
Mr. S. Balasubramanian
Mr. A. Kashyap (w.e.f May 28, 2020)
Mr. B. Akshikar (w.e.f December 1, 2020)
Mr. C. Sharma (w.e.f December 1, 2020)
Mr. N. Hindia (w.e.f. June 01, 2018 upto March 22, 2020 and w.e.f January 4, 2021)
Ms. M. Priyam (upto August 31, 2020)
Ms. D. Jakate (upto January 31, 2021)
Ms. S. Zota (w.e.f March 23, 2020 upto December 31, 2020)
Mr. G. Kotian (w.e.f. October 01, 2018 upto October 31, 2019)
Mr. N. Sudrik (w.e.f. October 01, 2018 upto October 31, 2019)
Ms. S. Ghosh(w.e.f August 25, 2020 upto December 1, 2020)

Related Party disclosures (continued)

2 The following transactions were carried out with the related parties in the ordinary course of business:

(i) Dividend paid to parties referred to in item 1(i) above:

(Rupees in lakhs)

	Year ended March 31, 2021	Year ended March 31, 2020
Glaxo Group Limited, U.K.	219,49.38	121,94.10
GlaxoSmithKline Pte Limited, Singapore	171,37.45	95,20.80
Eskaylab Limited, U.K.	42,33.60	23,52.00
Burroughs Wellcome International Limited, U.K.	24,19.20	13,44.00

(ii) Details relating to parties referred to in items 1(i), 1(ii) and 1(iii) above:

(Rupees in lakhs)

	Holding company/ultimate holding company 1(i)		Subsidiary of the company 1(ii)		Other companies in the GSK Group 1(iii)	
	Year ended March 31, 2021	Year ended March 31, 2020	Year ended March 31, 2021	Year ended March 31, 2020	Year ended March 31, 2021	Year ended March 31, 2020
1 Purchase of materials/traded goods	-	-	3,62.48	-	619,20.62	634,52.35
2 Sale of materials/sale of products	-	-	-	-	63.17	23.92
3 Sale of laptops	-	-	-	-	-	28.56
4 Expenses recharged to other companies	-	36.05	29.89	35.34	26,95.55	27,93.64
5 Expenses recharged by other companies	49.56	-	-	-	96,35.07	74,67.46
6 Manufacturing charges recovered	-	-	4,65.95	-	4,31.95	13,84.54
7 Clinical research and data management recoveries	-	-	-	-	9,36.45	8,98.26
8 Liabilities written back	-	-	-	-	77.24	-
9 Employee benefit liabilities transferred to a related party	-	-	-	-	19.86	13.51
10 Outstanding receivables at the period end	-	-	4,04.06	-	7,29.68	7,30.82
11 Outstanding payables at the period end	46.17	-	-	35.58	118,94.44	56,77.24
12 Cross charges recoverable at the period end	-	-	-	-	4.82	1,25.22

(iii) Details relating to persons referred to in item 1(iv) above:

(Rupees in lakhs)

	Year ended March 31, 2021	Year ended March 31, 2020
1 Remuneration/commission/sitting fees	37,93.20	40,91.89
2 Payments under the long-term incentive plan	2,95.47	5,16.49